Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction FDA approval… Read More
A vaccine manufactured in plants and developed in Canada LONDON, U.K. — Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted… Read More
In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of patients with moderate to severe Crohn’s disease treated with upadacitinib (45 mg once daily for… Read More
Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022 Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive… Read More
Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the… Read More
